Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Byun, Jung-Ick | - |
dc.contributor.author | Moon, Jangsup | - |
dc.contributor.author | Kim, Do-Yong | - |
dc.contributor.author | Shin, Hyerim | - |
dc.contributor.author | Sunwoo, Jun-Sang | - |
dc.contributor.author | Lim, Jung-Ah | - |
dc.contributor.author | Kim, Tae-Joon | - |
dc.contributor.author | Lee, Woo-Jin | - |
dc.contributor.author | Lee, Han Sang | - |
dc.contributor.author | Jun, Jin-Sun | - |
dc.contributor.author | Park, Kyung-Il | - |
dc.contributor.author | Lee, Soon-Tae | - |
dc.contributor.author | Jung, Keun-Hwa | - |
dc.contributor.author | Jung, Ki-Young | - |
dc.contributor.author | Lee, Sang Kun | - |
dc.contributor.author | Chu, Kon | - |
dc.date.accessioned | 2021-08-11T14:24:28Z | - |
dc.date.available | 2021-08-11T14:24:28Z | - |
dc.date.issued | 2017-09-05 | - |
dc.identifier.issn | 0028-3878 | - |
dc.identifier.issn | 1526-632X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7219 | - |
dc.description.abstract | Objective: To evaluate the long-term (for up to 3 months) efficacy and safety of single or combined therapy with midodrine and pyridostigmine for neurogenic orthostatic hypotension (OH). Methods: This was a randomized, open-label clinical trial. In total, 87 patients with symptomatic neurogenic OH were enrolled and randomized to receive 1 of 3 treatments: midodrine only, pyridostigmine only, or midodrine 1 pyridostigmine. The patients were followed up at 1 and 3 months after treatment. The primary outcome measures were improvement in orthostatic blood pressure (BP) drop at 3 months. Secondary endpoints were improvement of the orthostatic BP drop at 1 month and amelioration of the questionnaire score evaluating OH-associated symptoms. Results: Orthostatic systolic and diastolic BP drops improved significantly at 3 months after treatment in all treatment groups. Orthostatic symptoms were significantly ameliorated during the 3-month treatment, and the symptom severity was as follows: midodrine only, midodrine 1 pyridostigmine, pyridostigmine only group. Mild to moderate adverse events were reported by 11.5% of the patients. Conclusions: Single or combination treatment with midodrine and pyridostigmine was effective and safe in patients with OH for up to 3 months. Midodrine was better than pyridostigmine at improving OH-related symptoms. Clinicaltrials. gov identifier: NCT02308124. Classification of evidence: This study provides Class IV evidence that for patients with neurogenic OH, long-term treatment with midodrine alone, pyridostigmine alone, or both midodrine and pyridostigmine is safe and has similar effects in improving orthostatic BP drop up to 3 months. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
dc.title | Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1212/WNL.0000000000004340 | - |
dc.identifier.scopusid | 2-s2.0-85028863004 | - |
dc.identifier.wosid | 000409172500020 | - |
dc.identifier.bibliographicCitation | Neurology, v.89, no.10, pp 1078 - 1086 | - |
dc.citation.title | Neurology | - |
dc.citation.volume | 89 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1078 | - |
dc.citation.endPage | 1086 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.subject.keywordPlus | ACETYLCHOLINESTERASE INHIBITION | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | AGENT | - |
dc.subject.keywordAuthor | orthostatic hypotension | - |
dc.subject.keywordAuthor | Midodrine | - |
dc.subject.keywordAuthor | Pyridostigmine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.